The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 08, 2019

Filed:

Dec. 19, 2016
Applicant:

Metabasis Therapeutics, Inc., San Diego, CA (US);

Inventors:

Feng Tian, Fairfax, VA (US);

Qun Dang, Westfield, NJ (US);

G. Sridhar Prasad, San Diego, CA (US);

Wenyu Li, San Diego, CA (US);

Brett C. Bookser, San Diego, CA (US);

Nicholas Brian Raffaele, San Diego, CA (US);

Mark D. Erion, Del Mar, CA (US);

Assignee:

Metabasis Therapeutics, Inc., San Diego, CA (US);

Attorney:
Int. Cl.
CPC ...
C07D 213/81 (2006.01); A61K 31/44 (2006.01); C07F 9/6558 (2006.01); C07F 9/58 (2006.01); C07F 9/653 (2006.01); C07F 9/6539 (2006.01); C07F 9/6571 (2006.01); C07F 9/6512 (2006.01); C07F 9/6561 (2006.01); C07F 9/6509 (2006.01); C07F 9/6541 (2006.01);
U.S. Cl.
CPC ...
C07F 9/65586 (2013.01); A61K 31/44 (2013.01); C07D 213/81 (2013.01); C07F 9/58 (2013.01); C07F 9/587 (2013.01); C07F 9/653 (2013.01); C07F 9/6512 (2013.01); C07F 9/6539 (2013.01); C07F 9/6541 (2013.01); C07F 9/65122 (2013.01); C07F 9/65395 (2013.01); C07F 9/65397 (2013.01); C07F 9/65583 (2013.01); C07F 9/65616 (2013.01); C07F 9/650952 (2013.01); C07F 9/650964 (2013.01); C07F 9/657181 (2013.01);
Abstract

The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.


Find Patent Forward Citations

Loading…